ReviewBiomolecules2021
The Role of Androgens and Androgen Receptor in Human Bladder Cancer.
Review in Biomolecules, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.
- Impact of Androgen Suppression Therapy on the Risk and Prognosis of Bladder Cancer: A Systematic Review and Meta-Analysis.Frontiers in oncology · 2021Pooled it
- Metastasis development in non-muscle-invasive bladder cancer.Nature reviews. Urology · 2025Review
- Research progress on circular RNA in the regulation of drug resistance in genitourinary cancers.Cellular and molecular life sciences : CMLS · 2025Review
- Tracing the Evolution of Sex Hormones and Receptor-Mediated Immune Microenvironmental Differences in Prostate and Bladder Cancers: From Embryonic Development to Disease.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Sex-specific associations of sex hormone binding globulin and risk of bladder cancer.Open medicine (Warsaw, Poland) · 2025Article
- Bladder cancer biomarkers.Exploration of targeted anti-tumor therapy · 2025Review
- Prognostic feature based on androgen-responsive genes in bladder cancer and screening for potential targeted drugs.BioData mining · 2024Article
- Sex differences in cancer and immunotherapy outcomes: the role of androgen receptor.Frontiers in immunology · 2024Review
- Exploring the Relationship betweenGenes · 2023Article
- Stranger Things: New Roles and Opportunities for Androgen Receptor in Oncology Beyond Prostate Cancer.Endocrinology · 2023Review
- Cheminformatic Analysis and Machine Learning Modeling to Investigate Androgen Receptor Antagonists to Combat Prostate Cancer.ACS omega · 2023Article
- Regulation of the tumor immune microenvironment by cancer-derived circular RNAs.Cell death & disease · 2023Review
- Cytoplasmic Androgen Receptor, CD24 Expression and Smoking Intensity to Urothelial Carcinoma of the Bladder Invasiveness: A Cross-Sectional Study.Research and reports in urology · 2023Article
- Syngeneic model of carcinogen-induced tumor mimics basal/squamous, stromal-rich, and neuroendocrine molecular and immunological features of muscle-invasive bladder cancer.Frontiers in oncology · 2023Article
- A comprehensive review on methotrexate containing nanoparticles; an appropriate tool for cancer treatment.Molecular biology reports · 2022Review
- LncRNA SNHG1 Facilitates Tumor Proliferation and Represses Apoptosis by Regulating PPARγ Ubiquitination in Bladder Cancer.Cancers · 2022Article
- Establishment of an optimized orthotopic bladder cancer model in mice.BMC urology · 2022Article
- Hypogonadism and urologic surgeries: a narrative review.Translational andrology and urology · 2022Review
- Genetically supported causality between benign prostate hyperplasia and urinary bladder neoplasms: A mendelian randomization study.Frontiers in genetics · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Bladder cancer (urothelial carcinoma) is one of the most frequently diagnosed neoplasms, with an estimated half a million new cases and 200,000 deaths per year worldwide. This pathology mainly affects men. Men have a higher risk (4:1) of developing bladder cancer than women. Cigarette smoking and exposure to chemicals such as aromatic amines, and aniline dyes have been established as risk factors for bladder cancer and may contribute to the sex disparity. Male internal genitalia, including the urothelium and prostate, are derived from urothelial sinus endoderm; both tissues express the androgen receptor (AR). Several investigations have shown evidence that the AR plays an important role in the initiation and development of different types of cancer including bladder cancer. In this article, we summarize the available data that help to explain the role of the AR in the development and progression of bladder cancer, as well as the therapies used for its treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.